Ranking Invest
Switch to English

Kymera Therapeutics, Inc.

Segmento: Healthcare Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Indicadores Básicos

Valor de Mercado

$ 3.04 Bi

IVR

-

IVR2

-0.20

Índices de Previsibilidade

Faturamento

0.40

Lucro

0.16

Margem

0.48

Índices de Tendência

Faturamento

-1.87

Lucro

-8.34

Margem

-5.48

Índices de Endividamento

DIV/PAT

-0.00

DIV/L4T

0.02

Dívida Líquida

-$ 3.64 Mi

Patrimônio Líquido

$ 786.23 Mi

L4T

-$ 240.88 Mi

MM4T

-771.99%

Dívidas
Gráfico Lucro/Faturamento X Trimestre